MEK and PI3K inhibition in solid tumors: rationale and evidence to date
| Autor: | E. Jokinen, J.P. Koivunen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Medical Oncology, Vol 7 (2015) |
| Druh dokumentu: | article |
| ISSN: | 1758-8340 1758-8359 17588340 |
| DOI: | 10.1177/1758834015571111 |
| Popis: | PI3K-AKT-mTOR and Ras-Raf-MEK-ERK are the most commonly altered oncogenic pathways in solid malignancies. There has been a lot of enthusiasm to develop inhibitors to these pathways for cancer therapy. Unfortunately, the antitumor activities of single-agent therapies have generally been disappointing, excluding B-Raf mutant melanoma and renal cell cancer. Preclinical studies have suggested that concurrent targeting of the PI3K-AKT-mTOR and Ras-Raf-MEK-ERK pathways is an active combination in various solid malignancies. In the current work, we review the preclinical data of the PI3K and MEK dual targeting as a cancer therapy and the results of early-phase clinical trials, and propose future directions. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|